CLYBL and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy: Our modeling results indicate that standard dosing regimens achieve therapeutically appropriate exposures in Dravet syndrome patients as young as 6 months, supporting the safe and effective use of CLB and STP co-therapy in this population.